Kate Lines

Dr. Kate Lines is an Emerging Leader Research Fellow at Oxford Brookes University, School of Biological and Medical Sciences. She leads her own research group investigating epigenetic mechanisms in cancer, particularly endocrine cancers and neuroendocrine tumours (NETs). She holds a BSc(Hons) in Biochemistry from the University of Liverpool and a PhD in Molecular Oncology from the Barts Cancer Institute, with over 10 years of postdoctoral experience at the University of Oxford.

Her research focuses on:

• Epigenetic regulation of gene expression (DNA methylation, histone organization, microRNA) in cancer
• Role of MEN1, ATRX, and DAXX mutations in endocrine and neuroendocrine tumors
• Calcium signaling pathways in pituitary tumorigenesis
• Development of preclinical models via the NET Models Consortium

Recent publications (2022-2025) demonstrate a strong emphasis on endocrine oncology, with themes spanning epigenetic dysregulation, calcium signaling, genetic mutations (e.g., MEN1, GNAQ/GNA11), and therapeutic modeling. Over 50% of articles focus on neuroendocrine tumors, and 30% explore calcium receptor mechanisms.

She holds editorial roles at Endocrine Oncology and Endocrinology Insights and serves as the UK Research Ambassador for the NET Cancer Foundation, driving public engagement in cancer research. She leads the NET Models Consortium to advance tumor modeling and collaborates internationally on endocrine cancer studies.